Yang Liu, OncoC4 co-founder, CEO & CSO
March 20, 2023 11:35 AM EDTUpdated 04:39 PM
Deals

BioN­Tech to pay $200M up­front in CT­LA-4 an­ti­body de­vel­op­ment, com­mer­cial­iza­tion deal

Paul Schloesser

Associate Editor

BioN­Tech is branch­ing out in­to CT­LA-4 as part of a deal with the crew be­hind On­coIm­mune.

BioN­Tech and On­coC4 put out

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times